GSK

GSK plc

Add to Watchlist

Advanced Chart

46.860

-0.08(-0.170%)1D

Line

Candle

YTD

High

47.120

Open

46.850

VWAP

46.91

Vol

5.03M

Mkt Cap

95.15B

Low

46.570

Amount

235.86M

EV/EBITDA(TTM)

7.22

Total Shares

2.04B

86.35B

EV/OCF(TTM)

11.76

P/S(TTM)

2.23

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

8.28B

+3.64%

1.200

-0.3%

7.81B

+3.92%

0.615

+6.1%

8.42B

+3.7%

1.262

-2.36%

Estimates Revision

The market is revising Upward the revenue expectations for GSK plc (GSK) for FY2025, with the revenue forecasts being adjusted by 0.27% over the past three months. During the same period, the stock price has changed by 24.36%.

Revenue Estimates for FY2025

Revise Upward

+0.27%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.08%

In Past 3 Month

Stock Price

Go Up

+24.36%

In Past 3 Month

2 Analyst Rating

-8.24% Downside

Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 43.00 USD with a low forecast of 41.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

0 Sell

Hold

-8.24% Downside

Current: 46.860

Low

41.00

Averages

43.00

High

45.00

-8.24% Downside

Current: 46.860

Low

41.00

Averages

43.00

High

45.00

Guggenheim

Buy

downgrade

$4 -> $3

2025-10-28

Reason

Guggenheim

Price Target

$4 -> $3

2025-10-28

downgrade

Buy

Reason

Guggenheim lowered the firm's price target on Scynexis (SCYX) to $3 from $4 and keeps a Buy rating on the shares. The firm, which is updating its company model following the recent announcement that the company resolved their differences with GSK (GSK) on the restart of the MARIO trial for ibrexafungerp in invasive candidiasis, notes that its price target cut is mainly due to the loss of some of the potential milestone payments for ibrexafungerp.

Jefferies

Buy

initiated

£2,000

2025-10-27

Reason

Jefferies

Price Target

£2,000

2025-10-27

initiated

Buy

Reason

Jefferies assumed coverage of GSK with a Buy rating and 2,000 GBp price target. At a 30% discount, GSK "offers significant upside skew" and all that is required is for the new CEO to buy some time via an efficiency program given that there are green shoots within the pipeline and room for business development, the analyst tells investors.

Stifel

David Grossman

Buy

maintain

$320

2025-09-22

Reason

Stifel

David Grossman

Price Target

$320

2025-09-22

maintain

Buy

Reason

Stifel analyst David Grossman reiterated a Buy rating and $320 price target on Veeva (VEEV) after the company said that Bristol Myers (BMY) committed to Veeva Vault CRM, marking yet another top-20 Pharma customer formally committing to the platform, joining the likes of Merck (MRK), Novo Nordisk (NVO), GSK (GSK), Bayer (BAYRY), and Astellas (ALPMY). The firm noted that the company also got a verbal commitment from Gilead Sciences (GILD). While Monday's announcement is not incremental, the formal announcement is a reminder of Veeva's progress in converting the IB to the new platform, the analyst tells investors in a research note.

JPMorgan

NULL -> Underweight

downgrade

2025-08-04

Reason

JPMorgan

Price Target

2025-08-04

downgrade

NULL -> Underweight

Reason

JPMorgan lowered the firm's price target on GSK to 1,400 GBp from 1,460 GBp and keeps an Underweight rating on the shares.

Morgan Stanley

Underweight

downgrade

2025-07-21

Reason

Morgan Stanley

Price Target

2025-07-21

downgrade

Underweight

Reason

Morgan Stanley lowered the firm's price target on GSK to 1,290 GBp from 1,355 GBp and keeps an Underweight rating on the shares.

Morgan Stanley

Underweight

downgrade

2025-07-18

Reason

Morgan Stanley

Price Target

2025-07-18

downgrade

Underweight

Reason

Morgan Stanley lowered the firm's price target on GSK to 1,290 GBp from 1,355 GBp and keeps an Underweight rating on the shares. The firm updated the company's model for currency moves and reduced Blenrep sales ahead of the Q2 report. Morgan Stanley cut its peak Blenrep sales estimate to GBP 500M from BBP 1.4B citing the "low probability" of a U.S. approval.

See All Ratings

Valuation Metrics

The current forward P/E ratio for GSK plc (GSK.N) is 10.40, compared to its 5-year average forward P/E of 10.15. For a more detailed relative valuation and DCF analysis to assess GSK plc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

10.15

Current PE

10.40

Overvalued PE

13.89

Undervalued PE

6.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

8.18

Current EV/EBITDA

7.38

Overvalued EV/EBITDA

10.02

Undervalued EV/EBITDA

6.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

2.14

Current PS

35.67

Overvalued PS

3.60

Undervalued PS

0.68

Financials

Annual

Quarterly

FY2025Q3

YoY :

+10.62%

11.52B

Total Revenue

FY2025Q3

YoY :

+23.19%

3.76B

Operating Profit

FY2025Q3

YoY :

+3262.23%

2.89B

Net Income after Tax

FY2025Q3

YoY :

-3400.00%

0.66

EPS - Diluted

FY2025Q3

YoY :

+5.85%

1.79B

Free Cash Flow

FY2025Q3

YoY :

+4.01%

73.86

Gross Profit Margin - %

FY2025Q3

YoY :

-2.65%

13.21

FCF Margin - %

FY2025Q3

YoY :

+2996.30%

25.08

Net Margin - %

FY2025Q3

YoY :

+93.60%

18.74

ROIC

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

16.5M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

2.7M

Volume

6-9

Months

2.8M

Volume

0-12

Months

16.1M

Volume

Bought

0-3

0.0

Volume

Months

3-6

6.3M

Volume

Months

6-9

12.9M

Volume

Months

0-12

7.0M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

8.0K

USD

3-6

Months

24.0K

USD

6-9

Months

16.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

16.0K

USD

Months

6-9

8.0K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

16.5M

USD

Months

GSK News & Events

Events Timeline

2025-10-30 (ET)

2025-10-30

06:03:45

FDA Takes Steps to Speed Up Biosimilar Development and Reduce Medication Prices

2025-10-29 (ET)

2025-10-29

06:41:46

GSK Revises FY25 Forecast, Anticipating Core EPS Growth of 10%-12%

2025-10-29

06:38:27

GSK announces Q3 core EPS of 55p, reflecting a 14% increase at constant exchange rates.

News

9.5

10-29NASDAQ.COM

GSK Exceeds Q3 Earnings and Sales Projections, Shares Rise on Increased 2025 Outlook

4.5

10-29WSJ

Global Markets Show Varied Trends Before U.S. Interest Rate Announcement

7.0

10-29WSJ

GSK Increases Forecast Following Sales and Earnings Increase

People Also Watch

Becton Dickinson and Co

Republic Services Inc

208.240

USD

-0.80%

FAQ

What is GSK plc (GSK) stock price today?

The current price of GSK is 46.86 USD — it has decreased -0.17 % in the last trading day.

GSK

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

GSK News & Events

Events Timeline

News

People Also Watch

FAQ

What is GSK plc (GSK) stock price today?

What is GSK plc (GSK)'s business?

What is the price predicton of GSK Stock?

What is GSK plc (GSK)'s revenue for the last quarter?

What is GSK plc (GSK)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for GSK plc (GSK)'s fundamentals?

How many employees does GSK plc (GSK). have?

What is GSK plc (GSK) market cap?